Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 5;12(10):e0185981.
doi: 10.1371/journal.pone.0185981. eCollection 2017.

Treatment of canine leishmaniasis with marbofloxacin in dogs with renal disease

Carmen Pineda  1   2 , Escolastico Aguilera-Tejero  1   2 , Maria C Morales  1 , Silvia Belinchon-Lorenzo  3 , Luis C Gomez-Nieto  3 , Pablo Garcia  1 , Julio M Martinez-Moreno  2 , Maria E Rodriguez-Ortiz  4 , Ignacio Lopez  1   2
Affiliations

Treatment of canine leishmaniasis with marbofloxacin in dogs with renal disease

Carmen Pineda et al. PLoS One. .

Abstract

Treatment of canine leishmaniasis (CanL) represents a challenge. Due to the high prevalence of renal disease associated to CanL, it is important to find an effective drug that does not damage the kidneys. Marbofloxacin has been shown to be effective and well tolerated in non-azotemic dogs with leishmaniasis. To evaluate the safety and efficacy of marbofloxacin in dogs with leishmaniasis and decreased renal function, 28 dogs suffering from leishmaniasis and chronic kidney disease (CKD) were treated with oral marbofloxacin at 2 mg/Kg/day for 28 days. During treatment dogs were assessed by performing weekly physical exams, measuring blood pressure and evaluating blood and urine parameters. Lymph node aspirations were also obtained at days 0 and 28. The global clinical score decreased significantly, from 6.2±3.4 to 4.7±3.1 (p = 0.0001), after treatment. Marbofloxacin also decreased parasitic load in 72% of the dogs. No significant differences in plasma creatinine, urine specific gravity, urinary concentrations of cystatin C, ferritin and urinary protein loss were detected during treatment. A transient but significant decrease in blood pressure was detected up to day 14 (from 180.1±36.6 to 166.0±32.7 mmHg; p = 0.016). Moreover, dogs showed a significant increase in plasma albumin concentration (from 15.0±5.2 to 16.6±3.9 g/L; p = 0.014) and a significant decrease in globulin concentration (from 59.0±18.1 to 54.1±18.0 g/L; p = 0.005). The results demonstrate that, in addition to being effective for treatment of CanL, marbofloxacin is a very safe drug in dogs with CKD and leishmaniasis.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The funder (Vetoquinol) was not involved in implementing the study, data collection or preparation of the manuscript. Vetoquinol exclusively provided marbofloxacin. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Clinical scores before (at day 0) and after (at day 28) treatment with marbofloxacin in the dogs under study.
Values are expressed as the mean±standard deviation. ap<0.01 vs day 0.
Fig 2
Fig 2. Concentrations of plasma creatinine (A), plasma urea (B) and urine protein to creatinine (UPC) ratio (C) on days 0, 7, 14, 21 and 28 of treatment with marbofloxacin in the dogs under study.
Values are expressed as the mean±standard deviation.
Fig 3
Fig 3. Blood pressure measurement on days 0, 7, 14, 21 and 28 of treatment with marbofloxacin in the dogs under study.
Values are expressed as the mean±standard deviation. ap<0.02 vs day 0, bp<0.02 vs day 7.
Fig 4
Fig 4. Principal components analysis plot.
Interrelation between the main parameters studied at day 0 (A) and at day 28 (B). Alb: albumin; AbTiter: antibody titer; Crea: creatinine; CScore: clinical score; DBP: diastolic blood pressure; Glob: globulins; P: phosphate; ParLoad: parasitic load; PCV: packed cell volume; SBP: systolic blood pressure; UCystatin: urine cystatin C; UFerritin: urine ferritin; UPC: urine protein to creatinine ratio.
See this image and copyright information in PMC

References

    1. Petanides TA, Koutinas AF, Mylonakis ME, Day MJ, Saridomichelakis MN, Leontides LS, et al. Factors associated with the occurrence of epistaxis in natural canine leishmaniasis (Leishmania infantum). J Vet Intern Med. 2008;22:866–872. doi: 10.1111/j.1939-1676.2008.0129.x - DOI - PubMed
    1. Dujardin JC, Campino L, Cañavate C, Dedet JP, Gradoni L, Soteriadou K, et al. Spread of vector-borne diseases and neglect of Leishmaniasis, Europe. Emerg Infect Dis. 2008;14:1013–1018. doi: 10.3201/eid1407.071589 - DOI - PMC - PubMed
    1. Mettler M, Grimm F, Naucke TJ, Maasjost C, Deplazes P. [Canine leishmaniosis in Central Europe: retrospective survey and serological study of imported and travelling dogs]. Berl Munch Tierarztl Wochenschr. 2005;118:37–44 (Article in German, with English abstract). - PubMed
    1. Solano-Gallego L, Koutinas A, Miró G, Cardoso L, Pennisi MG, Ferrer L, et al. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet Parasitol. 2009;165:1–18. doi: 10.1016/j.vetpar.2009.05.022 - DOI - PubMed
    1. Solano-Gallego L, Miró G, Koutinas A, Cardoso L, Pennisi MG, Ferrer L et al. LeishVet guidelines for the practical management of canine leishmaniosis. Parasit Vectors. 2011;4:86 doi: 10.1186/1756-3305-4-86 - DOI - PMC - PubMed